SGS announces expansion and integration of chemistry & microbiology testing offer following Canadian acquisition
Testing services for cosmeceuticals, natural health products and medical marijuana from facilities in Canada.
SGS has announced that further to the acquisition of Quality Compliance Laboratories Inc. (QCL) in December 2015, its global network now offers chemistry and microbiology testing services for cosmeceuticals, natural health products and medical marijuana from facilities in Canada.
The acquisition of QCL has seen the incorporation of all 65 highly skilled professionals at its two Canadian sites into SGS’s global network of laboratories. The facilities, in Montreal and Markham, Toronto, have a combined laboratory space of over 10,000 sq. ft., and investment has already been made to equip the Markham site with new walk-in stability chambers.
The facilities are GMP compliant and are licensed/registered with, and inspected by, both Health Canada and the FDA. The services offered complement SGS’s existing life science portfolio by providing local testing services within Quebec, while expanding markets served to include nutraceuticals, medical devices, cosmetics and veterinary products.
New capabilities within the two facilities include ICP-MS/ICP-OES for elemental impurities analysis, fully automated tablet dissolution apparatuses, flow-through USP dissolution apparatus (USP #4), and Vitek for bacterial identification. Alongside the company’s existing facility in Mississauga, SGS can now offer a comprehensive service provision of analytical testing for pharmaceutical and biopharmaceutical products, raw materials and packaging, and medical devices capacity throughout Canada.
“This acquisition will have a positive impact for our customers as we can now offer increased flexibility and capacity when and where clients need support,” commented Michael Lindsay, Vice President Life Sciences Unit, SGS Canada Inc. “SGS continues to increase its service capacity and offering for clients to ensure that we can meet future market and regulatory needs in order that they can safely develop, launch and maintain products globally.”
Related News
-
News Patients vs Pharma – who will the Inflation Reduction Act affect the most?
The Inflation Reduction Act brought in by the Biden administration in 2022 aims to give better and more equitable access to healthcare in the USA. However, pharma companies are now concerned about the other potential costs of such legislation. -
News CPHI Podcast Series: What does the changing US Pharma market mean for industry and patients alike?
In this week's episode of the CPHI Podcast Series Lucy Chard, Digital Editor for CPHI Online is joined by James Manser to discuss the political and market changes in the US pharma field. -
News CPHI Barcelona Annual Report illuminates industry trends for 2024
The CPHI Annual Survey comes into it’s 7th year to report on the predicted trends for 2024. Over 250 pharma executives were asked 35 questions, with their answers informing the industry landscape for the next year, spanning all major pharma marke... -
News Which 10 drugs are open to price negotiation with Medicare in the USA?
The Centres for Medicare & Medicaid Services, under the Biden administration in the USA, has released a list of the 10 drugs that will be open to price negotiations as part of the new legislation under the Inflation Reduction Act (IRA). -
News EU Medical Devices Regulation causes unintended disappearances of medical devices for children, doctors state
Doctor groups and associations have appealed to the EU to correct the EU Medical Devices Regulation law that may cause unintended shortages of essential drug and medical devices for children and rare disease patients. -
News 10 Major Drug Approvals So Far in 2023
Last year, 37 novel drugs were approved by the FDA, this was a high number for such a category, and covered many fields including oncology, demonstrating how promising further research is, and how it is only continuing to build. To date, there are alre... -
News Detecting Alzheimer's disease with a simple lateral flow test
A novel rapid diagnostic test for early-stage Alzheimer's disease has been developed using a biomarker binder from Aptamer Group along with technology from Neuro-Bio, the neurodegenerative disease experts. -
News CPHI Podcast Series: outsourcing and manufacturing trends
Listen to the CPHI Podcast Series this June to hear Gil Roth of the PBOA speak with Digital Editor Lucy Chard about the biggest trends and topics to watch in pharma outsourcing and manufacturing at the minute.
Position your company at the heart of the global Pharma industry with a CPHI Online membership
-
Your products and solutions visible to thousands of visitors within the largest Pharma marketplace
-
Generate high-quality, engaged leads for your business, all year round
-
Promote your business as the industry’s thought-leader by hosting your reports, brochures and videos within your profile
-
Your company’s profile boosted at all participating CPHI events
-
An easy-to-use platform with a detailed dashboard showing your leads and performance